PDSB - PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference | Benzinga
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, Chief Executive Officer of PDS Biotech, will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference being held September 26-28, 2023, in New York City. Details for the event are as follows:
2023 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 26, 2023
Event: Panel presentation
Time: 2:45 PM EDT
Investors can register for the webcast here.
Following the panel presentation, a webcast replay will be available on the Investor section of the company's website. For more information about the conference or to schedule one-on-one meetings, please contact your Cantor Fitzgerald representative directly.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical ...